How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/metastatic-human-epidermal-growth-factor-2-positive-carcinoma-of-breast.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Metastatic human epidermal growth factor 2 positive carcinoma of breast — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metastatic human epidermal growth factor 2 positive carcinoma of breast (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Metastatic human epidermal growth factor 2 positive carcinoma of breast, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Margenza	MARGETUXIMAB	Macrogenics Inc	HER2/neu Receptor Antagonist [EPC]	Receptor tyrosine-protein kinase erbB-2	2020-01-01
Tukysa	tucatinib	Seagen	Kinase Inhibitor [EPC]	ERBB2/ERBB3	2020-01-01
Tukysa	tukysa	Pfizer	Kinase Inhibitor [EPC]	ERBB2/ERBB3	2020-01-01
Enhertu	trastuzumab-deruxtecan	Daiichi Sankyo		Receptor tyrosine-protein kinase erbB-2	2019-01-01
Enhertu	Enhertu	Washington D.C. Veterans Affairs Medical Center		DNA topoisomerase 1, Receptor tyrosine-protein kinase erbB-2
MARGENZA	MARGETUXIMAB-CMKB	MACROGENICS INC	HER2/neu Receptor Antagonist [EPC]	Low affinity immunoglobulin gamma Fc region receptor III-A, Receptor tyrosine-protein kinase erbB-2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Daiichi Sankyo · 1 drug in Metastatic human epidermal growth factor 2 positive carcinoma of breast
MACROGENICS INC · 1 drug in Metastatic human epidermal growth factor 2 positive carcinoma of breast
Macrogenics Inc · 1 drug in Metastatic human epidermal growth factor 2 positive carcinoma of breast
Pfizer · 1 drug in Metastatic human epidermal growth factor 2 positive carcinoma of breast
Seagen · 1 drug in Metastatic human epidermal growth factor 2 positive carcinoma of breast
Washington D.C. Veterans Affairs Medical Center · 1 drug in Metastatic human epidermal growth factor 2 positive carcinoma of breast

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Metastatic human epidermal growth factor 2 positive carcinoma of breast:

Cite this brief

Drug Landscape (2026). Metastatic human epidermal growth factor 2 positive carcinoma of breast — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/metastatic-human-epidermal-growth-factor-2-positive-carcinoma-of-breast. Accessed 2026-06-10.

Metastatic human epidermal growth factor 2 positive carcinoma of breast full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing